优化接受阿基仑赛、替沙仑赛和利索仑赛治疗后的CAR-T监测期
这项回顾性研究纳入9个中心2018至2023年输注阿基仑赛、替沙仑赛和利索仑赛的475例患者,评估细胞因子释放综合征(CRS)和免疫效应细胞相关神经毒性综合征(ICANS)的发生与持续时间及非复发死亡原因。输注2周后新发CRS和ICANS极为罕见(分别为0%和0.7%),非复发死亡早期由ICANS驱动(至第28天1.1%),3个月内由感染驱动(1.2%)。
要点
- 输注2周后新发CRS为0%,新发ICANS为0.7%。
- 至第28天非复发死亡由ICANS驱动,比例为1.1%。
- 输注后3个月内非复发死亡由感染驱动,比例为1.2%。
核心结论
- 不同CAR-T产品间CRS和ICANS的发生率与持续时间存在差异,但输注2周后新发CRS和ICANS极为罕见。
- 非复发死亡早期由ICANS驱动,之后至3个月由感染驱动。
- 研究结果可能为减少患者身体和经济负担提供框架。
研究设计与样本
- 回顾性研究,纳入9个中心2018至2023年输注阿基仑赛、替沙仑赛和利索仑赛的475例患者。
主要发现
- 输注2周后新发CRS和ICANS极为罕见,分别为0%和0.7%的患者。
- 输注2周后无新发CRS病例,第三周发生1例新发ICANS。
- 非复发死亡至第28天由ICANS驱动,比例为1.1%。
- 非复发死亡至输注后3个月由感染驱动,比例为1.2%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CD19-directed chimeric antigen receptor T-cell (CAR T) therapies, including axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), and lisocabtagene maraleucel (liso-cel), have transformed the treatment landscape for B-cell non-Hodgkin lymphoma, showcasing significant efficacy but also highlighting toxicity risks such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). The US Food and Drug Administration has mandated patients remain close to the treatment center for 4 weeks as part of a Risk Evaluation and Mitigation Strategy to monitor and manage these toxicities, which, although cautious, may add to cost of care, be burdensome for patients and their families, and present challenges related to patient access and socioeconomic disparities. This retrospective study across 9 centers involving 475 patients infused with axi-cel, tisa-cel, and liso-cel from 2018 to 2023 aimed to assess CRS and ICANS onset and duration, as well as causes of nonrelapse mortality (NRM) in real-world CAR T recipients. Although differences were noted in the incidence and duration of CRS and ICANS between CAR T products, new-onset CRS and ICANS are exceedingly rare after 2 weeks after infusion (0% and 0.7% of patients, respectively). No new cases of CRS occurred after 2 weeks and a single case of new-onset ICANS occurred in the third week after infusion. NRM is driven by ICANS in the early follow-up period (1.1% until day 28) and then by infection through 3 months after infusion (1.2%). This study provides valuable insights into optimizing CAR T therapy monitoring, and our findings may provide a framework to reduce physical and financial constraints for patients.
引用
- Ahmed N, Wesson W, Lutfi F, et al. Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel. Blood Adv. 2024. PMID: 39042880. doi:10.1182/bloodadvances.2023012549
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。